Correspondence 0001683168-24-000853 from Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc.
Date: Feb. 9, 2024 · CIK: 0001402328 · Accession: 0001683168-24-000853
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276817
Letter
Sunshine Biopharma, Inc.
1177 Avenue of the Americas, 5th Floor
New York , NY 10036
February 9, 2024
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re: Sunshine Biopharma, Inc.
Registration Statement on Form S-1
File No. 333-276817
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Sunshine Biopharma, Inc. hereby respectfully requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time, February 12, 2024, or as soon as practicable thereafter.
Very truly yours,
Sunshine Biopharma, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Sunshine Biopharma, Inc.
1177 Avenue of the Americas,
5th Floor
New York , NY 10036
February 9, 2024
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re: Sunshine Biopharma, Inc.
Registration Statement on Form S-1
File No. 333-276817
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated
under the Securities Act of 1933, as amended, Sunshine Biopharma, Inc. hereby respectfully requests acceleration of the effectiveness
of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time,
February 12, 2024, or as soon as practicable thereafter.
Very truly yours,
Sunshine Biopharma, Inc.
By:
/s/ Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chief Executive Officer